Catalyst

Slingshot members are tracking this event:

Vanda Pharmaceuticals (VNDA) Expected to submit HETLIOZ filing to EU in 2018 for Smith Magenis Syndrome (SMS) indication

Source Link:
https://seekingalpha.com/article/4053316-vanda-pharmaceuticals-vnda-presents-cowen-company-37th-annual-health-care-conference

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
VNDA Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Aug 03, 2020
Occurred Source:
https://www.prnewswire.com/news-releases/fda-accepts-and-grants-priority-review-of-vandas-applications-for-hetlioz-tasimelteon-in-the-treatment-of-smith-magenis-syndrome-301104479.html
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords European Medicines Agency, Smith-magenis Syndrome, Hetlioz
About Us
Media Center
Connect with Us
© 2026 Slingshot Insights. All rights reserved.